NervGen Pharma Statistics

Total Valuation

NervGen Pharma has a market cap or net worth of CAD 210.83 million. The enterprise value is 193.67 million.

Market Cap	210.83M
Enterprise Value	193.67M

Important Dates

The last earnings date was Thursday, April 3, 2025.

Earnings Date	Apr 3, 2025
Ex-Dividend Date	n/a

Share Statistics

NervGen Pharma has 70.99 million shares outstanding. The number of shares has increased by 13.55% in one year.

Current Share Class	n/a
Shares Outstanding	70.99M
Shares Change (YoY)	+13.55%
Shares Change (QoQ)	-0.12%
Owned by Insiders (%)	2.79%
Owned by Institutions (%)	4.06%
Float	59.01M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	n/a
PB Ratio	81.83
P/TBV Ratio	99.84
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

EV / Earnings	-8.07
EV / Sales	n/a
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	n/a

Financial Position

The company has a current ratio of 1.12, with a Debt / Equity ratio of 0.04.

Current Ratio	1.12
Quick Ratio	1.05
Debt / Equity	0.04
Debt / EBITDA	n/a
Debt / FCF	n/a
Interest Coverage	n/a

Financial Efficiency

Return on equity (ROE) is -8,460.20% and return on invested capital (ROIC) is -3,580.97%.

Return on Equity (ROE)	-8,460.20%
Return on Assets (ROA)	-95.24%
Return on Invested Capital (ROIC)	-3,580.97%
Return on Capital Employed (ROCE)	-964.50%
Revenue Per Employee	n/a
Profits Per Employee	n/a
Employee Count	7
Asset Turnover	n/a
Inventory Turnover	n/a

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has increased by +40.76% in the last 52 weeks. The beta is 0.71, so NervGen Pharma's price volatility has been lower than the market average.

Beta (5Y)	0.71
52-Week Price Change	+40.76%
50-Day Moving Average	2.84
200-Day Moving Average	2.77
Relative Strength Index (RSI)	55.61
Average Volume (20 Days)	71,424

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

Revenue	n/a
Gross Profit	n/a
Operating Income	-24.93M
Pretax Income	-24.01M
Net Income	-24.01M
EBITDA	-24.87M
EBIT	-24.93M
Earnings Per Share (EPS)	-0.36

Full Income Statement

Balance Sheet

The company has 17.27 million in cash and 105,603 in debt, giving a net cash position of 17.16 million or 0.24 per share.

Cash & Cash Equivalents	17.27M
Total Debt	105,603
Net Cash	17.16M
Net Cash Per Share	0.24
Equity (Book Value)	2.58M
Book Value Per Share	0.04
Working Capital	2.11M

Full Balance Sheet

Cash Flow

Operating Cash Flow	-16.84M
Capital Expenditures	n/a
Free Cash Flow	n/a
FCF Per Share	n/a

Full Cash Flow Statement

Margins

Gross Margin	n/a
Operating Margin	n/a
Pretax Margin	n/a
Profit Margin	n/a
EBITDA Margin	n/a
EBIT Margin	n/a
FCF Margin	n/a

Dividends & Yields

NervGen Pharma does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-13.55%
Shareholder Yield	-13.55%
Earnings Yield	-11.39%
FCF Yield	n/a

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

Altman Z-Score	n/a
Piotroski F-Score	n/a